Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
PGEN
STRONG SELLPrecigen, Inc. · Healthcare · United States · $1.9B · Avg Vol: $26M/d
COMPANY DESCRIPTION
Precigen, Inc. is a biotechnology company developing gene and cell therapies to address unmet needs in oncology, autoimmune disorders, and infectious diseases, utilizing its advanced genomic engineering platform. The company's competitive moat is based on its proprietary UltraCAR-T and AdenoVerse technologies designed for rapid, flexible, and cost-effective therapeutic development. It aims to be a leader in the next generation of precision medicines.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 26.9M | 6.2M | 3.9M | 9.7M | -28.9% | 31.6M | 124.4M | 229.0M | 386.3% |
| EPS | 0.14 | -0.39 | -0.47 | -1.37 | — | -1.24 | — | — | — |
| Shares | 208.2M | 248.9M | 292.9M | 353.9M | +70.0% | 356.5M | — | — | — |
| Debt | 51.4M | 7.1M | 5.5M | 98.3M | 24.1% | 98.3M | — | — | — |
| Equity | 126.3M | 118.5M | 38.5M | 20.9M | -45.1% | — | — | — | — |
| Op CF | -65.0M | -66.9M | -68.2M | -87.8M | — | -115.3M | — | — | — |
| Inv CF | 226.4M | -3.1M | -20.7M | -1.5M | — | — | — | — | — |
| Fin CF | -155.3M | 29.6M | 110.6M | 90.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PGEN are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| PGEN | Precigen, Inc.(you) | $1.9B | 17 | STRONG SELL |
| ZBIO | Zenas BioPharma, Inc. | $1.9B | 16 | STRONG SELL |
| SNDX | Syndax Pharmaceuticals, Inc. | $1.8B | 17 | STRONG SELL |
| TYRA | Tyra Biosciences, Inc. | $1.8B | 20 | SELL |
| BHVN | Biohaven Ltd. | $2.2B | 19 | STRONG SELL |
| ZYME | Zymeworks Inc. | $1.7B | 19 | STRONG SELL |
| TSHA | Taysha Gene Therapies, Inc. | $1.6B | 18 | STRONG SELL |
| IMNM | Immunome, Inc. | $2.5B | 17 | STRONG SELL |
| MLYS | Mineralys Therapeutics, Inc. | $2.4B | 15 | STRONG SELL |
| COAG | Hemab Therapeutics Holdings, Inc. | $2.2B | 13 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.7%